BioWorld

Feb. 24, 2003

View Archived Issues

Monitoring Committee Suspends Enrollment In QLT, Xenova Trial

QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today) Read More

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Read More

Two Interleukin Molecules, IL-12 & IL-23, Duke It Out To Nail Guilt Or Innocence In Mouse Autoimmunity

Read More

Nasdaq Market Looking To Ease Rules For Continued Listing

Read More

Other News To Note

Read More

Appointments And Advancements

Read More